Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 15/20 | 0.44 |
| ▸ | PPARA | Q07869 | 13/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580738 | 0.83 | PARP10 (0.42) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL10738521 | 0.83 | MTNR1A (0.47) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL28840586 | 0.82 | PPARG (0.57) | CYP1A2PPARGPPARACES2CES1 | |
| SCHEMBL5533536 | 0.81 | PPARG (0.51) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL8955004 | 0.81 | TDP1 (0.45) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL5532010 | 0.81 | PPARG (0.54) | LDHAPPARGPPARA | |
| SCHEMBL9460207 | 0.79 | KMT2A (0.50) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL947767 | 0.79 | LTA4H (0.38) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL11300616 | 0.78 | L3MBTL1 (0.41) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL5698537 | 0.78 | CTSD (0.48) | GAAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118703564-A | Carrier and application thereof in improving production efficiency of momordica grosvenori fruits | 上海吉罗恩生物科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-102809559-B | Method for detecting halogenated aromatic organic matter | RES CT ECO ENVIRONMENTAL SCIEN | 2015-06-17 | — | — | CN | claimed |
| CN-118703564-A | Carrier and application thereof in improving production efficiency of momordica grosvenori fruits | 上海吉罗恩生物科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-111374126-A | Pesticide polymer synergist and application thereof in glyphosate preparation | 汕头市大千高新科技研究中心有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-102809559-B | Method for detecting halogenated aromatic organic matter | RES CT ECO ENVIRONMENTAL SCIEN | 2015-06-17 | — | — | CN | disclosed |
| WO-2007119984-A1 | SALICYLIC ACID DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | NEUROTECH CO., LTD. (KR) | 2007-10-25 | — | — | WO | disclosed |
| US-7015247-B2 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GUTTAG ALVIN | 2006-03-21 | — | — | US | disclosed |
| US-20030008833-A1 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GUTTAG ALVIN (US) | 2003-01-09 | — | — | US | disclosed |
| US-6436916-B1 | PHENOLIC ESTERS OF IBUPROFEN WITH SALICYLIC ACID OR ITS NONTOXIC SALTS USED AS ANTITUMOR AGENT | GUTTAG ALVIN (US) | 2002-08-20 | — | — | US | disclosed |
| US-20020065254-A1 | Ibuprofen-aspirin and hydroxymethylacylfulvene analogs | GUTTAG ALVIN (US) | 2002-05-30 | — | — | US | disclosed |
| US-4051170-A | Diphenoxyacetic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065254-A1 | Ibuprofen-aspirin and hydroxymethylacylfulvene analogs | PTGES3, HPGDS, PTGES | CYP1A2 945/4885GAA 4492/4885CYP2C9 233/4885 |
| US-20030008833-A1 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GALE, TPT1, HPSE | CYP1A2 3444/4885GAA 3216/4885CYP2C9 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.